IL1B and atherosclerosis: Humanin treatment also inhibits the high glucose-induced secretion of TNF-α and IL-1β and reduces the expression of VCAM-1 and E-selectin, thus preventing hyperglycaemia-induced attachment of the monocytes to the vascular cells, endothelial dysfunction and atherosclerosis progression [39].